Your browser doesn't support javascript.
loading
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Douillard, J Y; Siena, S; Cassidy, J; Tabernero, J; Burkes, R; Barugel, M; Humblet, Y; Bodoky, G; Cunningham, D; Jassem, J; Rivera, F; Kocákova, I; Ruff, P; Blasinska-Morawiec, M; Smakal, M; Canon, J L; Rother, M; Oliner, K S; Tian, Y; Xu, F; Sidhu, R.
Afiliación
  • Douillard JY; Department of Medical Oncology, Centre René Gauducheau, Nantes, France. Electronic address: jean-yves.douillard@ico.unicancer.fr.
  • Siena S; Division of Medical Oncology, Ospedale Niguarda Ca' Granda, Milan, Italy.
  • Cassidy J; Division of Cancer Sciences and Molecular Pathology, The Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Tabernero J; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Burkes R; Department of Medicine, Division of Hematology/Oncology, Mount Sinai Hospital, Toronto, Canada.
  • Barugel M; Department of Medical Oncology, Hospital de Gastroenterología, Buenos Aires, Argentina.
  • Humblet Y; Department of Medical Oncology, Université Catholique de Louvain, Brussels, Belgium.
  • Bodoky G; Department of Oncology, Szent Laszlo Hospital, Budapest, Hungary.
  • Cunningham D; Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Jassem J; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
  • Rivera F; Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Kocákova I; Oncology Department, Masarykuv Onkologicky Ustav, Brno, Czech Republic.
  • Ruff P; Department of Medical Oncology, University of Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa.
  • Blasinska-Morawiec M; Proliferative Diseases Branch, Copernicus Memorial Hospital, Lodz, Poland.
  • Smakal M; Department of Oncology, Institut Onkologie a Rehabilitace na Plesi s.r.o., Nová Ves pod Plesí, Czech Republic.
  • Canon JL; Department of Oncology and Hematology, Grand Hôpital de Charleroi, Charleroi, Belgium.
  • Rother M; Department of Oncology, The Credit Valley Hospital, Mississauga,Canada.
  • Oliner KS; Department of Medical Sciences, Amgen, Inc., Thousand Oaks.
  • Tian Y; Department of Biostatistics, Amgen, Inc., Thousand Oaks.
  • Xu F; Department of Biostatistics, Amgen, Inc., Thousand Oaks.
  • Sidhu R; Department of Global Development, Amgen, Inc., Thousand Oaks, USA.
Ann Oncol ; 25(7): 1346-1355, 2014 Jul.
Article en En | MEDLINE | ID: mdl-24718886
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2014 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2014 Tipo del documento: Article